دورية
Oral Calcitriol as a New Therapeutic Agent in Localized and Systemic Scleroderma
| العنوان: | Oral Calcitriol as a New Therapeutic Agent in Localized and Systemic Scleroderma |
|---|---|
| المؤلفون: | Humbert, Philippe, Aubin, François, Dupond, Jean Louis, Delaporte, Emmanuel |
| المصدر: | Archives of Dermatology; July 1995, Vol. 131 Issue: 7 p850-851, 2p |
| مستخلص: | We read the recent case report by Hulshof et al1 in the October 1994 issue of the Archives with interest. The authors described three patients with generalized morphea who were treated with calcitriol (1,25-dihydroxyvitamin D3) in an oral dose of 0.5 to 0.75 μg per day. After 3 to 7 months of treatment, the authors observed a beneficial effect on joint mobility and skin extensibility. Since our first report in 19902 demonstrating the beneficial effect of oral calcitriol in local- ized scleroderma, we conducted a study in 11 patients with systemic sclerosis and seven patients with morphea that also showed the efficacy of oral calcitriol. To date, after a 2- to 36-month treatment period, we confirm our promising data, as published in two recent reports.3-5 Taken together, these results suggest that a high dose of oral calcitriol (mean dose, 1.75 μg/d) may be a useful therapeutic |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 0003987X 15383652 |
|---|---|
| DOI: | 10.1001/archderm.1995.01690190106026 |